Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

2seventy bio, Inc. - Common Stock (NQ: TSVT )

4.630 -0.180 (-3.74%)
Streaming Delayed Price Updated: 3:29 PM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
The Latest Analyst Ratings for 2seventy bio
Via Benzinga
Analyst Expectations for 2seventy bio's Future
Via Benzinga
Where 2seventy bio Stands With Analysts
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy
Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule... 
Via Talk Markets
Why Novonix Shares Are Trading Higher By 27%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 127.8% to $0.1269. The company recently reported second-quarter results. 
Via Benzinga
2seventy Bio's Cost Cuts Prudent But Analyst Says It Induces Lower Confidence In Lead Product
Guggenheim Partners downgraded 2seventy Bio Inc (NASDAQ: TSVT) to Neutral from Buy and  
Via Benzinga
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway
From 2seventy bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Via Benzinga
2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies
From 2seventy bio
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 175 companies set new 52-week lows. 
Via Benzinga
2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference
From 2seventy bio, Inc.
Via Business Wire
Around $3.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project. 
Via Benzinga
Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 300 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 155 companies set new 52-week lows. 
Via Benzinga
2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023
From 2seventy bio, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's trading, 103 companies set new 52-week lows. 
Via Benzinga
Earnings Scheduled For August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. 
Via Benzinga
2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference
From 2seventy bio
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 46 stocks hit new 52-week lows. 
Via Benzinga
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls
The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for  
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
Cancer Drug Trials Put On Hold After Patients Died
Recent reports from two drug companies that had been conducing separate clinical trials to evaluate cancer treatments reveal that the trials were halted due to the deaths of six participants, including... 
Via Benzinga
2seventy Bio Pauses Pediatric Blood Cancer Trial After Patient Death, Stock Plunges
2seventy Bio Inc (NASDAQ: TSVT) announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute Myeloid Leukemia (AML), has been paused by Seattle Children's, the company's partner and... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2023
Via Benzinga
2seventy Bio Stock Crumbles After A Patient Dies In Its Pediatric Cancer Study
The company is investigating whether the death is tied to the experimental drug. 
Via Investor's Business Daily
2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia
From 2seventy bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.